- Open
- 4.75
- High
- 4.80
- Low
- 4.40
- Close
- 4.67
- Change
- -0.35 (-7.37%)
- Volume
- 1,573,044
| 2 Nov 2026 | 07:00:09 | Board appointment & Completion of Board evolution |
| 12 Oct 2026 | 07:00:09 | Appointment of Chief Financial Officer |
| 22 Sept 2026 | 07:00:06 | Board Changes |
| 15 Sept 2026 | 07:01:01 | Interim Results |
| 9 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Oct 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Oct 2024 | Annual Report and Accounts (to 2023-12-31) |
Hvivo plc acts as a holding company with investments in its wholly owned subsidiaries, hVIVO Services Limited and hVIVO Inc. The primary business activity of hVIVO Services Limited involves conducting human challenge studies and providing laboratory services for clinical trials on behalf of commercial clients. The company serves the biopharmaceutical sector, focusing on accelerating the development of new therapies. It operates primarily in the United Kingdom and has minority investments in associates, including Prep Biopharm Limited and Imutex Limited.
| 2 Nov 2026 | 07:00:09 | Board appointment & Completion of Board evolution |
| 12 Oct 2026 | 07:00:09 | Appointment of Chief Financial Officer |
| 22 Sept 2026 | 07:00:06 | Board Changes |
| 15 Sept 2026 | 07:01:01 | Interim Results |
| 9 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Oct 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Oct 2024 | Annual Report and Accounts (to 2023-12-31) |
Hvivo plc acts as a holding company with investments in its wholly owned subsidiaries, hVIVO Services Limited and hVIVO Inc. The primary business activity of hVIVO Services Limited involves conducting human challenge studies and providing laboratory services for clinical trials on behalf of commercial clients. The company serves the biopharmaceutical sector, focusing on accelerating the development of new therapies. It operates primarily in the United Kingdom and has minority investments in associates, including Prep Biopharm Limited and Imutex Limited.
| 15 Sept 2026 |
| 07:00:05 |
| Chief Financial Officer Succession |
| 27 Aug 2026 |
| hVIVO buys CRS Berlin to expand into dermatology and women's health |
| 27 Aug 2026 | hVIVO buys CRS Berlin to expand into dermatology, women's health and Phase II trials |
| 23 Jul 2026 | hVIVO’s order book more than doubles despite softer first half |
| 2 Jun 2026 | hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker |
| 20 May 2026 | S&U, 88 Energy, Serval Resources, Shoe Zone, hVIVO - Small Cap Snapshot |
| 20 May 2026 | hVIVO to host capital markets day as it pitches broader clinical development role |
| 15 Sept 2026 |
| 07:00:05 |
| Chief Financial Officer Succession |
| 27 Aug 2026 |
| hVIVO buys CRS Berlin to expand into dermatology and women's health |
| 27 Aug 2026 | hVIVO buys CRS Berlin to expand into dermatology, women's health and Phase II trials |
| 23 Jul 2026 | hVIVO’s order book more than doubles despite softer first half |
| 2 Jun 2026 | hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker |
| 20 May 2026 | S&U, 88 Energy, Serval Resources, Shoe Zone, hVIVO - Small Cap Snapshot |
| 20 May 2026 | hVIVO to host capital markets day as it pitches broader clinical development role |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
HVOHvivo plc | £32m | -0.2% |
| £24m | +0.1% | |
| £21m | +0.1% | |
| £10m | -0.1% | |
| £6m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
HVOHvivo plc | £32m | -0.2% |
| £24m | +0.1% | |
| £21m | +0.1% | |
| £10m | -0.1% | |
| £6m | -0.7% |